G1 Therapeutics Inc (STU:G1H)
€ 6.39 0 (0%) Market Cap: 339.15 Mil Enterprise Value: 327.68 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 32/100

G1 Therapeutics Inc at B Riley Securities Oncology Conference (Virtual) Transcript

Jan 19, 2023 / 04:30PM GMT
Release Date Price: €5.59 (-6.95%)
Andrew Fleszar
B. Riley Securities, Inc., Research Division - Research Analyst

Good morning, everyone, and welcome to the B. Riley Virtual Oncology Conference. I'm Andy Fleszar, part of the biotech team here at B. Riley, and I'm pleased to introduce our next company, G1 Therapeutics. With me, I have CEO, Jack Bailey; CSO, Raj Malik; and CCO, Andrew Perry. Jack, Raj, Andrew, thank you for joining us today.

John E. Bailey
G1 Therapeutics, Inc. - CEO, President & Director

Great to be here, Andy. Thanks for having us.

Questions & Answers

Andrew Fleszar;John E. Bailey
B. Riley Securities, Inc., Research Division - Research Analyst;

While the COSELA launch in small cells has been the primary focus for many investors, attention is starting to shift to your upcoming read-out in colorectal cancer. So let's start the discussion there. Maybe give us a brief overview of COSELA and what's the magnitude of the opportunity in colorectal cancer relative to extensive stage small cell.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot